Indraprastha Medical Corporation reported a net profit of ₹55.85 crore for the quarter ended June 30, 2026, reflecting steady growth in its healthcare operations. The result represents an improvement over the ₹51.46 crore net profit recorded in the same quarter of the previous fiscal year. Total income from operations rose to ₹414.57 crore, compared to ₹371.96 crore in Q1FY25, indicating expanded service delivery and patient footfall at its facilities in New Delhi.

The company filed its unaudited financial results with the stock exchanges on August 6, 2026, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were approved by the Board of Directors and signed off by Managing Director Shivakumar Pattabhiraman. The full format of the financial statements is available on the company’s website and the respective exchange portals.

The rise in net profit was supported by a consistent expansion in top-line revenue, which grew by approximately 11.5% year-on-year. This growth trajectory suggests effective utilization of existing infrastructure and potential increases in average revenue per patient. The pre-tax profit stood at ₹74.82 crore, up from ₹68.31 crore in the prior year quarter, demonstrating improved operational efficiency before tax provisions.

What the Numbers Show

The proportional growth in both revenue and net profit indicates that Indraprastha Medical Corporation maintained stable operating margins during the quarter. With earnings per share increasing to ₹6.09 from ₹5.61 in the same period last year, shareholders benefited directly from the operational gains. The total comprehensive income for the period was ₹58.10 crore, slightly higher than the net profit due to other comprehensive income items, reflecting a balanced financial performance without significant non-operational volatility.

Indraprastha Medical Corporation Limited reported a net profit of ₹55.85 crore for the quarter ended June 30, 2026, marking an 8.5% year-on-year increase from ₹51.46 crore in Q1FY26. The healthcare provider’s revenue from operations expanded by 11.3% to ₹406.15 crore, up from ₹365.06 crore in the corresponding prior period, driven by higher patient inflows and increased professional charges to doctors. This growth underscores sustained demand for its services despite rising operational costs.

The Board of Directors approved the unaudited financial results at its meeting held on August 6, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by statutory auditors S N Dhawan & Co LLP in accordance with Standard on Review Engagements (SRE) 2410. Additionally, the Board fixed September 18, 2026, as the record date for determining shareholders entitled to the dividend for fiscal year 2025-26 and for participation in the upcoming Annual General Meeting (AGM).

Financial Performance Highlights

Revenue from operations stood at ₹406.15 crore, compared to ₹365.06 crore in Q1FY26. Other income rose by 22.0% to ₹8.42 crore from ₹6.90 crore, contributing to a total income increase of 11.5% to ₹414.57 crore. Total expenses grew by 11.9% to ₹339.75 crore, slightly outpacing revenue growth.

Key cost drivers included professional charges to doctors, which increased by 13.7% to ₹111.15 crore from ₹97.84 crore. Employee benefits expense rose by 12.3% to ₹72.96 crore, while cost of materials consumed grew by 11.6% to ₹70.13 crore. Other expenses increased by 8.5% to ₹72.10 crore. Profit before tax climbed 9.5% to ₹74.82 crore. Tax expense was recorded at ₹19.68 crore, including a deferred tax credit of ₹0.71 crore.

Corporate Actions and Governance

The Board approved convening the thirty-eighth Annual General Meeting on September 24, 2026, via video conferencing or other audio-visual means. The record date for dividend entitlement and AGM participation is set for September 18, 2026. Furthermore, the Board re-appointed M/s Devarajan Swaminathan and Co., Cost Accountants, as Cost Auditors for the financial year 2026-27, based on the Audit Committee’s recommendation. The company operates in a single segment—Healthcare—and has no subsidiaries, associates, or joint ventures as of June 30, 2026.

What the Numbers Show

The 11.3% revenue growth outpaced the 8.5% rise in net profit, indicating margin compression pressure. While top-line expansion was robust, total expenses grew at a slightly faster rate of 11.9%, primarily driven by a 13.7% increase in professional charges to doctors. This suggests that while patient inflow and service utilization are rising, the cost structure is adjusting accordingly, impacting bottom-line leverage in this quarter.